178 related articles for article (PubMed ID: 36811822)
1. Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
Verhoek A; Cheema P; Melosky B; Samson B; Shepherd FA; de Marinis F; John T; Wu YL; Heeg B; Van Dalfsen N; Bracke B; Miranda M; Shaw S; Moldaver D
Pharmacoecon Open; 2023 May; 7(3):455-467. PubMed ID: 36811822
[TBL] [Abstract][Full Text] [Related]
2. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
3. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
[TBL] [Abstract][Full Text] [Related]
4. Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Huo G; Song Y; Liu W; Cao X; Chen P
Front Pharmacol; 2024; 15():1300183. PubMed ID: 38606181
[No Abstract] [Full Text] [Related]
5. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (
Nilsson FOL; Gal P; Houisse I; Ivanova JI; Asanin ST
J Med Econ; 2021; 24(1):447-457. PubMed ID: 33754924
[TBL] [Abstract][Full Text] [Related]
7. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
Lemmon CA; Zabor EC; Pennell NA
Oncologist; 2022 May; 27(5):407-413. PubMed ID: 35285487
[TBL] [Abstract][Full Text] [Related]
8. Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
Vanderpoel J; Emond B; Ghelerter I; Milbers K; Lafeuille MH; Lefebvre P; Ellis LA
Pharmacoecon Open; 2023 Jul; 7(4):617-626. PubMed ID: 37074589
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis.
Wang J; Wu YL; Lu S; Wang Q; Li S; Zhong WZ; Wang Q; Li W; Wang B; Chen J; Cheng Y; Duan H; Li G; Shan L; Liu Y; Liu J; Huang X; Bolanos A; He J
JTO Clin Res Rep; 2024 Feb; 5(2):100621. PubMed ID: 38371194
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
11. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
Majem M; Goldman JW; John T; Grohe C; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Li S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Atagi S; Zeng L; Kulkarni D; Medic N; Tsuboi M; Herbst RS; Wu YL
Clin Cancer Res; 2022 Jun; 28(11):2286-2296. PubMed ID: 35012927
[TBL] [Abstract][Full Text] [Related]
12. Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA
Zhang SS; Ou SI
Lung Cancer (Auckl); 2022; 13():23-31. PubMed ID: 35506019
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
Ezeife DA; Kirk V; Chew DS; Nixon NA; Lee R; Le LW; Chan KK; Leighl NB
Lung Cancer; 2018 Nov; 125():1-7. PubMed ID: 30429004
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.
Rui M; Li H
Clin Ther; 2020 Nov; 42(11):2159-2170.e6. PubMed ID: 33028495
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer in China.
Zhou X; Du J; Xu G; Chen C; Zheng B; Chen J
Cancer Med; 2022 Dec; 11(23):4449-4456. PubMed ID: 35689472
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib in Resected
Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS;
N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
[No Abstract] [Full Text] [Related]
19. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]